How much has OpenEvidence raised?
OpenEvidence has about $700 million reported; the latest public valuation/status marker is $12 billion reported in January 2026.
- Total raised
- About $700 million reported
- Disclosed rounds
- 4
- Latest round
- Series D
- Latest valuation
- $12 billion reported in January 2026
- First raised
- 2025-02
- Notable backer
- Reported investors including GV, Nvidia, Blackstone
OpenEvidence's funding rounds
OpenEvidence's disclosed financing history shows capital raised for product, hiring, and market expansion.
- 2025-02Series A — $75 million; $1 billion valuationLead/backers: Sequoia Capital.
- 2025-07Series B — $210 million; $3.5 billion valuationLead/backers: GV and Kleiner Perkins.
- 2025-10Series C — $200 million; $6 billion valuationLead/backers: Reported growth investors.
- 2026-01Series D — $250 million; $12 billion valuationLead/backers: Reported investors including GV, Nvidia, Blackstone and others.
Sources:CNBC OpenEvidence funding coverageTechCrunch OpenEvidence coverage
How much has OpenEvidence raised in total?
OpenEvidence has about $700 million reported based on public reporting. 2025-02: Series A — $75 million, led/backed by Sequoia Capital ($1 billion valuation). 2025-07: Series B — $210 million, led/backed by GV and Kleiner Perkins ($3.5 billion valuation). 2025-10: Series C — $200 million, led/backed by Reported growth investors ($6 billion valuation). 2026-01: Series D — $250 million, led/backed by Reported investors including GV, Nvidia, Blackstone and others ($12 billion valuation).
Where debt, secondaries, or preferred-equity packages are included in public reporting, they are described as reported rather than converted into common-equity funding.
Who are OpenEvidence's investors?
The disclosed investor base includes Sequoia Capital; GV and Kleiner Perkins; Reported growth investors; Reported investors including GV, Nvidia, Blackstone and others. These investors matter because they indicate whether the company is optimized for venture-scale software growth, capital-intensive deployment, clinical development, or government procurement.
For sellers, investor quality is a useful signal, but procurement timing still depends on budget ownership and integration urgency.
Why did OpenEvidence's valuation move?
The latest public marker is $12 billion reported in January 2026. Valuation movement appears tied to progress in medical ai search, public customer/partner proof, and the broader investor appetite for AI-enabled category leaders.
No public source confirms profitability, so valuation should be treated as a financing-market signal rather than an operating-margin signal.
Is OpenEvidence profitable, and will it IPO?
OpenEvidence has not publicly disclosed audited profitability. IPO timing is not confirmed unless explicitly stated in company or news sources.
The practical read is that the company remains private and is using capital to extend product, hiring, regulatory, deployment, or R&D capacity.
What does OpenEvidence's funding mean if you sell into them?
The funding profile suggests budget exists for tools tied directly to medical ai search, security, compliance, infrastructure, hiring leverage, and customer deployment. Sellers should map pitches to a funded initiative rather than a generic productivity story.
The best outreach angle is to show how a product shortens deployment time, lowers risk, or improves measurable outcomes for the teams named in the leadership and product sections.
As of June 2026.Sources:OpenEvidence websiteCNBC OpenEvidence funding coverageTechCrunch OpenEvidence coverage
OpenEvidence — frequently asked questions
